Factor VIII inhibitors: a 50-year perspective
- 18 May 2011
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 17 (6), 831-838
- https://doi.org/10.1111/j.1365-2516.2011.02568.x
Abstract
Inhibitors of factor VIII (FVIII) have been studied for more than 50 years, but diagnostic and therapeutic challenges remain. To describe the features that distinguish alloantibodies from autoantibodies, list predisposing factors, and review methods for tolerance induction and autoantibody suppression. Review of key articles published during the past half-century that have advanced knowledge in this field. Alloantibodies generally bind to the A2 or C2 domains of FVIII and disrupt the formation of the FVIII-FIX complex. They exhibit type 1 reaction kinetics, are saturable by FVIII, and display anamnesis. In contrast, autoantibodies usually bind to the C2 domain of FVIII, interfering with phospholipid and von Willebrand factor binding. They have type-2 kinetics and are poorly neutralized by FVIII. Repeated exposures to FVIII induce tolerance in 70-80% of haemophiliacs with inhibitors, whereas drugs that deplete B-lymphocytes restore self-tolerance to FVIII in a similar percentage of non-haemophiliacs. Future work should focus on improving assays that detect and quantify inhibitors, examining the pathophysiology of inhibitor formation using contemporary immunologic tools, and investigating new treatment modalities. These should include agents to control bleeding with less thrombotic risk, more specific immunomodulating drugs to curtail antibody formation, and, for haemophilia patients, genetic therapies to provide FVIII resistant to or protected from inactivation by inhibitors.Keywords
This publication has 90 references indexed in Scilit:
- Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus reportHaemophilia, 2010
- Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic reviewJournal of Thrombosis and Haemostasis, 2010
- Inhibitor development: patient‐determined risk factorsHaemophilia, 2010
- Acquired haemophilia caused by non-haemophilic factor VIII gene variantsAnnals of Hematology, 2010
- Inhibitors of factor VIII in hemophilia.New England Journal of Medicine, 2009
- Inhibitors of Factor VIII in Black Patients with HemophiliaNew England Journal of Medicine, 2009
- Acquired Circulating Anticoagulants in Hemophilia ANew England Journal of Medicine, 1969
- The Immunologic Character of Acquired Inhibitors of Antihemophilic Globulin (Factor VIII) and the Kinetics of Their Interaction with Factor VIII*JCI Insight, 1967
- An Antitihaemophilic Globulin (Factor VIII) Inhibitor: Purification, Characterization and Reaction KineticsBritish Journal of Haematology, 1963
- A Method for the Study of Antihaemophilic Globulin Inhibitors with Reference to Six CasesBritish Journal of Haematology, 1959